CCT129957 |
| Catalog No.GC64388 |
CCT129957 est un dérivé indole et un puissant inhibiteur de la phospholipase C-γ (PLC-γ) avec une IC50 d'environ 3 μM et une GC50 de 15 μM. CCT129957 inhibe la libération de Ca2+ dans les cellules de carcinome épidermoÏde À ~15 μM.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 883098-58-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
CCT129957 is an indole derivative and a potent phospholipase C-γ (PLC-γ) inhibitor with an IC50 of ~3 μM and a GC50 of 15 μM. CCT129957 inhibits Ca2+ release in squamous carcinoma cells at ~15 μM[1][2].
The phenyl group on the left side sat in a lipophilic pocket formed of various amino acids. The predicted binding mode of CCT129957 displays a robust hydrogen bond pattern as well as a lipophilic contact[1].CCT129957 inhibits the cell growth of renal UO-31 and the breast T-47D cancer cell lines by ~60-70%[2].
[1]. Reynisson J, et al. The identification of novel PLC-gamma inhibitors using virtual high throughput screening. Bioorg Med Chem. 2009 Apr 15;17(8):3169-76.
[2]. Feng L, et al. The effect of PLC-γ2 inhibitors on the growth of human tumour cells. Eur J Med Chem. 2012 Aug;54:463-9.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *